AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25117817 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent trastuzumab (Arm C)
Number of subjects: 1365
Study 25117817 — intervention group
Group type: COMPARATOR
Intervention: Sequential trastuzumab after chemotherapy (Arm B)
Number of subjects: 1365
Study 25117817 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Arm A)
Number of subjects: 1365
Study 25117817 — intervention group
Group type: COMPARATOR
Intervention: Validation cohort (n=130)
Number of subjects: 1365
Study 22300946 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 15
Study 22300946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 15
Study 22300946 — intervention group
Group type: COMPARATOR
Intervention: HIV treatment-naive patients
Number of subjects: 15
Study 22300946 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall gene expression across all treatment groups
Number of subjects: 15
Study 22300946 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV-containing ARV regimens
Number of subjects: 15
Study 20465647 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pulse (SP) 0.3 ms
Number of subjects: 24
Study 20465647 — intervention group
Group type: COMPARATOR
Intervention: Super-long pulse (SL) 250 ms
Number of subjects: 24
Study 18045299 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (n = 17)
Number of subjects: 33
Study 18045299 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + sufentanil (n = 16)
Number of subjects: 33
Study 18045299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bupivacaine alone and Bupivacaine + sufentanil)
Number of subjects: 33
Study 16142594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin, 80 mg, p.o.
Number of subjects: 57
Study 16142594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 11864920 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab for 24 hours
Number of subjects: 167
Study 11864920 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab for 48 hours
Number of subjects: 167
Study 11864920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 10204904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream applied for 60 minutes
Number of subjects: 60
Study 10204904 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study 8849538 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsutured 6 mm frown incisions
Number of subjects: 30
Study 8849538 — intervention group
Group type: COMPARATOR
Intervention: Sutured 6 mm frown incisions
Number of subjects: 30
Study 2097777 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril with furosemide and propranolol
Number of subjects: 40
Study 2097777 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril with furosemide and propranolol
Number of subjects: 40
Study 2097777 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 40
Study 202205 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 11
Study 202205 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia without halothane
Number of subjects: 11
Study 31196453 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27454
Study 27429350 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 34
Study 27429350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25663767 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaotan Sanjie (XTSJ) decoction
Number of subjects: 0
Study 25663767 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-8 (IL-8)
Number of subjects: 0
Study 23549582 — intervention group
Group type: EXPERIMENTAL
Intervention: V710 vaccine, 60 μg (n = 4015)
Number of subjects: 8031
Study 23549582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4016)
Number of subjects: 8031
Study 22400901 — intervention group
Group type: EXPERIMENTAL
Intervention: Best medical care plus intermittent pneumatic compression
Number of subjects: 2800
Study 22400901 — intervention group
Group type: COMPARATOR
Intervention: Best medical care
Number of subjects: 2800
Study 19494217 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneously every 8 weeks
Number of subjects: 35
Study 19494217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19494217 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 35
Study 17962502 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-minute visit from a volunteer with a therapy dog
Number of subjects: 76
Study 17962502 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study 17962502 — intervention group
Group type: COMPARATOR
Intervention: 12-minute visit from a volunteer
Number of subjects: 76
Study 15121733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 5000 U/day plus low-dose aspirin
Number of subjects: 55
Study 15121733 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment intervention)
Number of subjects: 55
Study 11436644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 72
Study 9580193 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples with successive failed IVF cycles (group 1)
Number of subjects: 50
Study 9580193 — intervention group
Group type: COMPARATOR
Intervention: Infertile couples achieving a viable pregnancy with their first IVF attempt (group 2)
Number of subjects: 50
Study 9580193 — intervention group
Group type: COMPARATOR
Intervention: Population sample (group 3)
Number of subjects: 50
Study 7873221 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 50
Study 2979272 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 24924 (2.2 mg single oral dose)
Number of subjects: 20
Study 2979272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31558480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (arm 1)
Number of subjects: 46
Study 31558480 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide or Dacarbazine (arm 2)
Number of subjects: 46
Study 31558480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib after progression (arm 2X)
Number of subjects: 46
Study 30197142 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with 3 × 10^9 cfu of Mannheimia haemolytica (MH) suspended in 5 mL of sterile phosphate buffered saline (PBS) followed by a 120 mL wash PBS (n = 12)
Number of subjects: 24
Study 30197142 — intervention group
Group type: COMPARATOR
Intervention: Inoculation with 5 mL + 120 mL of sterile PBS (control; n = 12)
Number of subjects: 24
Study 30197142 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with 3 × 10^9 cfu of Mannheimia haemolytica (MH)
Number of subjects: 24
Study 27459375 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n = 46)
Number of subjects: 91
Study 27459375 — intervention group
Group type: COMPARATOR
Intervention: Control (standard maternity care, n = 45)
Number of subjects: 91
Study 24902453 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tidal volumes with larger apparatus dead space (DS group, 15 patients)
Number of subjects: 30
Study 24902453 — intervention group
Group type: COMPARATOR
Intervention: Positive end-expiratory pressure (PEEP, 15 patients)
Number of subjects: 30
Study 23753094 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based counselor-assisted problem solving (CAPS) intervention
Number of subjects: 132
Study 23753094 — intervention group
Group type: COMPARATOR
Intervention: Internet resource comparison (IRC)
Number of subjects: 132
Study 20545838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-afternoon nap (14:00-16:00 hours)
Number of subjects: 21
Study 20545838 — intervention group
Group type: COMPARATOR
Intervention: No nap (control group)
Number of subjects: 21
Study 20545838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep loss
Number of subjects: 21
Study 18543304 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60
Study 18543304 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study 15718847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly plus dietary counselling
Number of subjects: 25
Study 15718847 — intervention group
Group type: COMPARATOR
Intervention: Diet counselling alone
Number of subjects: 25
Study 15718847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once-weekly
Number of subjects: 25
Study 12358250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran (15 g b.i.d.)
Number of subjects: 12
Study 12358250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran
Number of subjects: 12
Study 10327492 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis players
Number of subjects: 633
Study 10327492 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 633
Study 8566253 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Number of subjects: 157
Study 8566253 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 157
Study 2007377 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg aspirin daily (group 1)
Number of subjects: 79
Study 2007377 — intervention group
Group type: COMPARATOR
Intervention: 100 mg aspirin daily (group 2)
Number of subjects: 79
Study 7036708 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg/day and 240 mg/day)
Number of subjects: 12
Study 7036708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7036708 — intervention group
Group type: EXPERIMENTAL
Intervention: Open label diltiazem therapy
Number of subjects: 12
Study 30680828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly administration of Cetuximab at 500 mg/m2
Number of subjects: 0
Study 30680828 — intervention group
Group type: COMPARATOR
Intervention: Weekly administration of Cetuximab at 250 mg/m2
Number of subjects: 0
Study 27135752 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week rehabilitative CRF self-management exercise intervention
Number of subjects: 72
Study 27135752 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 27645341 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 150mg or 300mg monthly
Number of subjects: 2236
Study 24472402 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-705498 12 mg
Number of subjects: 40
Study 24472402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22820409 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 40
Study 22820409 — intervention group
Group type: COMPARATOR
Intervention: Wait-List control group
Number of subjects: 40
Study 19563331 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 10
Study 19563331 — intervention group
Group type: COMPARATOR
Intervention: Non-activated laser (control)
Number of subjects: 10
Study 17538805 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% terbinafine emulsion gel
Number of subjects: 84
Study 17538805 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% terbinafine emulsion gel
Number of subjects: 84
Study 17538805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 15003135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions including nutritional advice
Number of subjects: 0
Study 15003135 — intervention group
Group type: COMPARATOR
Intervention: Current schemes for evaluating evidence
Number of subjects: 0
Study 11422706 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 h stay (overnight) in a general surgical ward
Number of subjects: 28
Study 11422706 — intervention group
Group type: COMPARATOR
Intervention: Day procedure unit (DPU) stay
Number of subjects: 28
Study 9891541 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction platinum based chemotherapy
Number of subjects: 76
Study 9891541 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Number of subjects: 76
Study 9891541 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 positive cells
Number of subjects: 76
Study 9891541 — intervention group
Group type: EXPERIMENTAL
Intervention: bcl-2 positive cells
Number of subjects: 76
Study 8006266 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression cardiopulmonary resuscitation
Number of subjects: 53
Study 8006266 — intervention group
Group type: COMPARATOR
Intervention: Standard manual cardiopulmonary resuscitation
Number of subjects: 53
Study 2642536 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide plus dexamethasone
Number of subjects: 91
Study 2642536 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone alone
Number of subjects: 91
Study 2642536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 4827463 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (Valium), 20 mg daily for at least 5 consecutive days
Number of subjects: 15
Study 4827463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29411269 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalid® 25 mg tablet (test formulation)
Number of subjects: 42
Study 29411269 — intervention group
Group type: COMPARATOR
Intervention: Revlimid® 25 mg capsule (reference formulation)
Number of subjects: 42
Study 29411269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 42
Study 27543211 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (TCS) alone
Number of subjects: 21
Study 27543211 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (TCS) + dilute bleach bath
Number of subjects: 21
Study 27543211 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy children)
Number of subjects: 21
Study 25082395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 400 mg/day
Number of subjects: 0
Study 25082395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 600 mg/day
Number of subjects: 0
Study 25082395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21923279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intravitreal pegaptanib injection, n=250
Number of subjects: 500
Study 21923279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pegaptanib), n=250
Number of subjects: 500
Study 20847623 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Number of subjects: 108
Study 20847623 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoanal ultrasonography
Number of subjects: 108
Study 20847623 — intervention group
Group type: COMPARATOR
Intervention: Control group (score of 2 or less on Pescatori incontinence scale)
Number of subjects: 108
Study 18077056 — intervention group
Group type: EXPERIMENTAL
Intervention: vitamin/mineral/guaraná supplement
Number of subjects: 129
Study 18077056 — intervention group
Group type: COMPARATOR
Intervention: placebo drink
Number of subjects: 129
Study 15068851 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic immunizations with recombinant gp160
Number of subjects: 0
Study 15068851 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunizations with HIV DNA during HAART treatment
Number of subjects: 0
Study 15068851 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with gp160
Number of subjects: 0
Study 15068851 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term HAART treatment
Number of subjects: 0
Study 15068851 — intervention group
Group type: COMPARATOR
Intervention: Single structured therapy interruption (STI)
Number of subjects: 0
Study 11176590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (Floxin otic)
Number of subjects: 0
Study 11176590 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin/clavulanate (Augmentin)
Number of subjects: 0
Study 9699891 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 9699891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7916278 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated MUKC vaccine (3 doses)
Number of subjects: 2479
Study 7916278 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated MUKC vaccine (3 doses, different procedures)
Number of subjects: 2479
Study 7916278 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated MUKC vaccine (secondary immunization)
Number of subjects: 2479
Study 2556518 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet on back pain
Number of subjects: 0
Study 2556518 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16301238 — intervention group
Group type: COMPARATOR
Intervention: 225 mg ropivacaine (7.5 mg/mL) alone (control group)
Number of subjects: 40
Study 16301238 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg ropivacaine combined with 75 mug clonidine (clonidine group)
Number of subjects: 40
Study 16301238 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine group
Number of subjects: 40
Study 16301238 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 31204605 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints (OS; n= 24)
Number of subjects: 89
Study 31204605 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT; n= 21)
Number of subjects: 89
Study 31204605 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (C; n= 19)
Number of subjects: 89
Study 31204605 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints associated with counseling (OSC; n= 25)
Number of subjects: 89
Study 31932513 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 0.8 mg with enalapril 10 mg
Number of subjects: 20702
Study 31932513 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg alone
Number of subjects: 20702
Study 31932513 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid treatment
Number of subjects: 20702
Study 30378521 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy support practices
Number of subjects: 133
Study 30378521 — intervention group
Group type: EXPERIMENTAL
Intervention: Coercive control and indulgent feeding practices
Number of subjects: 133
Study 30378521 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative role modelling
Number of subjects: 133
Study 28643321 — intervention group
Group type: EXPERIMENTAL
Intervention: Global End-Diastolic Volume (GEDV) monitoring
Number of subjects: 74
Study 28643321 — intervention group
Group type: COMPARATOR
Intervention: Central Venous Pressure (CVP) monitoring
Number of subjects: 74
Study 26550817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of hyaluronic acid (HA) + oral viscosupplementation (IA)
Number of subjects: 100
Study 26550817 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection of hyaluronic acid (HA) only
Number of subjects: 100
Study 22887343 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg selenium (N=234)
Number of subjects: 699
Study 22887343 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg selenium (N=233)
Number of subjects: 699
Study 22887343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=232)
Number of subjects: 699
Study 21489720 — intervention group
Group type: EXPERIMENTAL
Intervention: Woven polyglycolic acid conduit
Number of subjects: 42
Study 21489720 — intervention group
Group type: COMPARATOR
Intervention: Autogenous vein
Number of subjects: 42
Study 19493391 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg
Number of subjects: 813
Study 19493391 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 813
Study 16202498 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized composite resin crown (SRCC) with ferrule (2 mm), no post
Number of subjects: 48
Study 16202498 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized composite resin crown (SRCC) with ferrule and glass fiber post
Number of subjects: 48
Study 16202498 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized composite resin crown (SRCC) with ferrule and zirconium post
Number of subjects: 48
Study 16202498 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized composite resin crown (SRCC) with ferrule and cast gold post
Number of subjects: 48
Study 16202498 — intervention group
Group type: EXPERIMENTAL
Intervention: Root-canal-treated with composite resin
Number of subjects: 48
Study 16202498 — intervention group
Group type: COMPARATOR
Intervention: Untreated teeth
Number of subjects: 48
Study 15023883 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP)
Number of subjects: 5218
Study 15023883 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure, mean arterial pressure, and pulse pressure
Number of subjects: 5218
Study 15023883 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive medication use
Number of subjects: 5218
Study 11304594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-polydioxanone
Number of subjects: 20
Study 11304594 — intervention group
Group type: COMPARATOR
Intervention: 2-0 nylon
Number of subjects: 20
Study 9266229 — intervention group
Group type: EXPERIMENTAL
Intervention: Home flow test (HFT)
Number of subjects: 172
Study 8390508 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 25 mg every 12 h for 5 days
Number of subjects: 24
Study 8390508 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 200 mg every 12 h for 5 days
Number of subjects: 24
Study 8390508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3824009 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental appendectomy
Number of subjects: 100
Study 3824009 — intervention group
Group type: COMPARATOR
Intervention: No appendectomy
Number of subjects: 100
Study 30328014 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise program
Number of subjects: 70
Study 27994257 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion (n = 8)
Number of subjects: 50
Study 27994257 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (n = 25)
Number of subjects: 50